WELT

What WELT does

WELT Corporation (웰트 주식회사) is a South Korea-based digital therapeutics company founded in 2016 and headquartered in Seoul's Gangnam district. The company develops prescription software-based medical treatments, with its flagship product SleepQ (슬립큐) — an MFDS-approved, CE-certified digital therapeutic device for chronic insomnia delivered as a mobile application. SleepQ administers a structured 6-week cognitive behavioral therapy for insomnia (CBT-I) program, combining a proprietary sleep restriction therapy algorithm that generates personalized bedtime and wake-time prescriptions, 1:1 phone coaching with certified sleep counselors (three calls plus night-hour support from 10 PM to 5 AM), AI-assisted consultation via the 'Sleep Doctor Ssam' chatbot, and progressively structured educational content reviewed by psychiatrists. Clinical data cited by the company indicates a 55% or greater reduction in sleep onset latency and treatment effects sustained up to 24 months post-program.

The business model is prescription-based: patients consult a physician in person or via teleconsultation, receive a SleepQ prescription, and pay ₩250,000 KRW for the 6-week program, with Korean national health insurance and supplemental medical insurance reducing patient out-of-pocket to approximately ₩25,000 KRW in many cases. Distribution combines a network of 12+ major Korean university hospital partners (including Seoul National University Hospital, Severance Hospital, and Catholic University Seoul St. Mary's Hospital), a teleconsultation channel, and Google Play / Apple App Store availability for activated prescriptions. WELT is pursuing European expansion through ongoing clinical trials in Germany, and management has publicly indicated pipeline expansion into anxiety, addiction, and depression indications under a 'digital pharmaceutical company' positioning.

Name

WELT

Legal name

웰트 주식회사

Website

https://weltcorp.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

WELT (웰트) is a Seoul-based digital therapeutics company whose flagship product, SleepQ, is an MFDS-approved and CE-certified mobile prescription digital therapeutic delivering a 6-week cognitive behavioral therapy program for chronic insomnia patients in South Korea, distributed through university hospital prescriptions and teleconsultation channels with planned European expansion.

Ownership category

akta.pro rank

Product category

Digital Therapeutics

NAICS

Outpatient Mental Health and Substance Abuse Centers (621420)

SIC

Services-Health Services (8000), Services-Prepackaged Software (7372)

akta.pro primary industry

Pulmonology & Sleep Medicine Telemedicine Platforms (HLALAGAF)

Keywords

• Digital therapeutics
• Insomnia treatment
• Cognitive behavioral therapy
• Sleep medicine software
• Medical device apps

Headquarters

HQ city

Seocho

HQ country

South Korea

HQ region

Asia

Offices1 record

Markets served

GTM type

B2C

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Digital Therapeutics Prescription Program: WELT generates revenue through its SleepQ digital therapeutic program which requires medical prescription. Patients pay for doctor consultation and the 6-week intensive treatment program including personalized sleep management, counselor coaching calls, and daily CBT-I content. The program is partially covered by Korean national health insurance (National Health Insurance) and supplemental insurance (실손 의료보험), creating a hybrid payment model where patients may pay as little as ₩25,000 with insurance coverage.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Core offering

WELT develops and operates SleepQ (슬립큐), a prescription digital therapeutic mobile application for chronic insomnia treatment. The product delivers a 6-week cognitive behavioral therapy for insomnia (CBT-I) program, including a proprietary sleep restriction algorithm that prescribes personalized bedtime and wake-up times, daily educational content designed by psychiatrists, 1:1 phone coaching with certified sleep counselors, and an AI-powered sleep expert chatbot.

Product overview

WELT operates as a digital therapeutics company with a single flagship product: 슬립큐 (SleepQ), a mobile app-based digital treatment device for insomnia. The product delivers cognitive behavioral therapy for insomnia (CBT-i) through a structured 6-week program, combining 1:1 coaching calls with sleep counselors, personalized bedtime/wake time prescriptions based on sleep restriction therapy algorithms, and educational content designed by psychiatrists. The company positions itself as a 'digital pharmaceutical company' offering prescription-based treatment accessible via telemedicine consultations.

Differentiator

Problem solved

Functional benefit

Brands

• SleepQ (슬립큐): Digital therapeutic application for insomnia treatment using cognitive behavioral therapy (CBT-I). The app received approval from Korea's Ministry of Food and Drug Safety and CE certification for European markets.

Products and services

• SleepQ (슬립큐) A prescription-based digital therapeutic mobile application that delivers a 6-week cognitive behavioral therapy for insomnia (CBT-I) program for adults with chronic insomnia. Includes a proprietary sleep restriction therapy algorithm for personalized bedtime/wake-time prescriptions, 1:1 phone coaching with certified sleep counselors (3 calls), daily educational content reviewed by psychiatrists, relaxation therapy, sleep diary tracking, automated insurance claim document issuance, and an AI chatbot (Sleep Doctor Ssam). Approved by Korean MFDS (제호23-511호) and CE certified for European markets.

Quantifiable outcome

• 55%+ reduction in sleep onset latency (time to fall asleep)
• +2 more outcomes

Named customers12 records

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Severance Hospital (세브란스병원)coreStrategic or Co-development Partner · 14 June 2024Severance Hospital is a key development and prescription partner for SleepQ. The product was developed with participation of psychiatrists from Severance Hospital's Department of Psychiatry, and it became the first major hospital to prescribe SleepQ following regulatory approval. The hospital serves as a clinical validation partner.

Scale indicators6 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Somzz: Korea's first MFDS-approved prescription digital therapeutic for insomnia, directly competing with SleepQ in the same Korean hospital channel and reimbursement pathway. WELT explicitly positions itself as the second-mover entrant in this same category.
• Big Health (Sleepio): US/UK-based digital therapeutics company offering Sleepio, a CBT-I program for insomnia — the same evidence-based therapy that SleepQ delivers. Both target clinical-grade sleep treatment through digital channels, with overlapping product functionality and physician-referral GTM.
• Nox Health: Sleep health company offering enterprise sleep programs including CBT-I components, serving employer and healthcare channels. Comparable focus on clinical-grade insomnia intervention via scalable digital delivery.

Broad incumbents

• Pear Therapeutics: Pioneer in prescription digital therapeutics (Somryst for insomnia, reSET for substance use disorder) — direct product precedent for SleepQ's regulatory and commercial model. While Pear filed for bankruptcy in 2023, its Somryst product is the most comparable US FDA-cleared insomnia DTx benchmark.
• Headspace Health: Ginger and Headspace merged to form Headspace Health, offering mental health and sleep content via subscription and employer channels. Operates in overlapping behavioral health and sleep wellness category but with a consumer/employer GTM rather than prescription model.
• Calm: Consumer sleep, meditation, and mental wellness app with extensive sleep-specific content (Sleep Stories). Indirect competitor addressing the same end-customer (insomnia sufferers) via a non-prescription, consumer-led model.

Emerging players

• BetterHelp: Largest online therapy platform offering licensed therapist access, including CBT modalities that overlap with CBT-I. Competes for the same anxiety/insomnia patient population, though via human therapists rather than digital prescription device.
• Dreem: Digital sleep company combining a wearable headband with behavioral sleep programs, including CBT-I elements. Adjacent approach to insomnia treatment through combined hardware/software offering.
• Talkspace: Online therapy platform offering CBT-based behavioral health support that addresses insomnia among other conditions. Comparable telehealth-to-therapy delivery model targeting employer and consumer health benefits markets.

Others

• Oura: Consumer sleep-tracking ring with growing health subscription services. While not a treatment, it serves the same insomnia-prone consumer base and increasingly overlaps via partnerships with sleep coaching and CBT-I content providers.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/weltcorp
• YouTubeyoutube.com/results?search_query=WELT+sleepq
• Facebookfacebook.com/weltcorp
• LinkedInlinkedin.com/company/weltcorp
• Instagraminstagram.com/welt_corp

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds5 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about WELT